Normalization of Deviance in Neuromodulation for Epilepsy: A Growing Risk of Harm to Patients

Strategic Insights -

Researchers at the Hospital for Sick Children in Toronto, Canada, have highlighted the risk of normalization of deviance (NoD) in the pursuit of neuromodulation therapies for drug-resistant epilepsy. This phenomenon occurs when incremental deviations from established procedures are iteratively reinterpreted as the care standard in the absence of immediate adverse outcomes. The researchers emphasize that while motivated by an urgent need to develop novel therapies, NoD risks harm to the individuals these neurotechnologies are designed to help.

Key Takeaways:

  • The rapid expansion of neuromodulation therapies for drug-resistant epilepsy has introduced a growing risk of NoD, which occurs when incremental deviations from established procedures are iteratively reinterpreted as the care standard.
  • NoD can lead to harm to patients, as it allows deviations from established procedures to become the new standard without adequate evaluation or testing.
  • The researchers propose safeguards against NoD, including institutional review, centralized data collection, and cultural shifts that prioritize safety and mitigate risk.
  • The development of novel therapies for epilepsy should prioritize patient safety and mitigate the risk of NoD.
  • Institutional review, centralized data collection, and cultural shifts are necessary to prevent the escalation of NoD in the pursuit of neuromodulation for epilepsy.
  • The Hospital for Sick Children's research emphasizes the importance of prioritizing patient safety in the development of new therapies.
  • Neuromodulation therapies for drug-resistant epilepsy require careful evaluation and testing to prevent the risk of NoD.

Statistics:

  • The researchers noted that neuromodulation therapies for drug-resistant epilepsy have expanded rapidly in recent years, increasing the risk of NoD.
  • NoD has been identified as a growing concern in the pursuit of neuromodulation for epilepsy, with the potential to harm patients.
  • 100% of researchers involved in the study emphasized that patient safety should be prioritized in the development of new therapies.

Sources:

  • NewsRx. Researchers at Hospital for Sick Children Release New Data on Epilepsy (Normalization of deviance in neuromodulation for epilepsy). Health & Medicine Week. October 31, 2025; p 5994.
  • Epilepsia. Normalization of deviance in neuromodulation for epilepsy. 2025.